Agios Pharmaceuticals Inc (AGIO) 40.67 $AGIO
Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
Business Wire - Thu Apr 17, 7:01AM CDT
--- Third Agios Program to Enter Clinic in Less than a Year -
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:30AM CDT
Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%. One benefited from positive preliminary data from an early-stage clinical trial. Another surged...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Agios Taps Wall Street Off Early Data, Aims For $75M
Ben Fidler, The Motley Fool - Motley Fool - Thu Apr 10, 8:53AM CDT
Agios Pharmaceuticals gave investors its first glimpse of encouraging, but early human clinical data a few days ago, and saw its shares soar as a result. Now, it's looking to cash in. Cambridge, MA-based Agios wants to raise up to $75 million...
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 09, 4:08PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR), BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 8:04AM CDT
Agios Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 28% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Tue Apr 08, 7:09AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Biotech of the Week: Agios Pharmaceuticals
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 7:03PM CDT
As part of their weekly show, Biotech Banter , Fool contributor Brian Orelli and health-care bureau chief Max Macaluso occasionally run a segment highlighting a biotech. This week's honor goes to Agios Pharmaceuticals , which IPOed last year. ...
Why Vocus, Agios Pharmaceuticals, and Questcor Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 4:15PM CDT
For a second consecutive trading session, the broad-based S&P 500 got absolutely rocked. Despite a lack of critical economic data today, investors took time to take profits as fears continue to build that the winding down of the Federal...
This Relative Strength Play Is Ready to Explode
at The Street - Mon Apr 07, 2:08PM CDT
Rocket Fuel is displaying relative strength during this market weakness. Here's how to trade it.
Why Agios Pharmaceuticals Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals , a clinical-stage...
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Is Now the Time to Invest in Agios Pharmaceuticals, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 07, 10:17AM CDT
Shares of Agios Pharmaceuticals spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited...
Strong Tumor Response Seen From Agios Pharma Cancer Metabolism Drug
at The Street - Mon Apr 07, 7:40AM CDT
Patients with advanced blood cancer respond to treatment with Agios' AG-221, according to study results presented Sunday.
Agios’s Blood Cancer Drug Shines in First Clinical Test
Ben Fidler, The Motley Fool - Motley Fool - Sun Apr 06, 7:20PM CDT
When David Schenkein left Genentech to lead Agios Pharmaceuticals in 2009, part of the draw was the fact that the Cambridge, MA-based start-up was positioning itself as a trailblazer in a raw field of oncology —cancer metabolism. The idea,...
Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers
Business Wire - Sun Apr 06, 9:30AM CDT
--- Data Presented at AACR Corroborate Company's Precision Medicine Approach in Targeting Cancer Metabolism; Company to Host Investor Webcast on April 6 -
Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
Business Wire - Thu Apr 17, 7:01AM CDT
--- Third Agios Program to Enter Clinic in Less than a Year -
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:30AM CDT
Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%. One benefited from positive preliminary data from an early-stage clinical trial. Another surged...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Agios Taps Wall Street Off Early Data, Aims For $75M
Ben Fidler, The Motley Fool - Motley Fool - Thu Apr 10, 8:53AM CDT
Agios Pharmaceuticals gave investors its first glimpse of encouraging, but early human clinical data a few days ago, and saw its shares soar as a result. Now, it's looking to cash in. Cambridge, MA-based Agios wants to raise up to $75 million...
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 09, 4:08PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR), BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 8:04AM CDT
Agios Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 28% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Tue Apr 08, 7:09AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Biotech of the Week: Agios Pharmaceuticals
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 7:03PM CDT
As part of their weekly show, Biotech Banter , Fool contributor Brian Orelli and health-care bureau chief Max Macaluso occasionally run a segment highlighting a biotech. This week's honor goes to Agios Pharmaceuticals , which IPOed last year. ...
Why Vocus, Agios Pharmaceuticals, and Questcor Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 4:15PM CDT
For a second consecutive trading session, the broad-based S&P 500 got absolutely rocked. Despite a lack of critical economic data today, investors took time to take profits as fears continue to build that the winding down of the Federal...
This Relative Strength Play Is Ready to Explode
at The Street - Mon Apr 07, 2:08PM CDT
Rocket Fuel is displaying relative strength during this market weakness. Here's how to trade it.
Why Agios Pharmaceuticals Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals , a clinical-stage...
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Is Now the Time to Invest in Agios Pharmaceuticals, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 07, 10:17AM CDT
Shares of Agios Pharmaceuticals spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited...
Strong Tumor Response Seen From Agios Pharma Cancer Metabolism Drug
at The Street - Mon Apr 07, 7:40AM CDT
Patients with advanced blood cancer respond to treatment with Agios' AG-221, according to study results presented Sunday.
Agios’s Blood Cancer Drug Shines in First Clinical Test
Ben Fidler, The Motley Fool - Motley Fool - Sun Apr 06, 7:20PM CDT
When David Schenkein left Genentech to lead Agios Pharmaceuticals in 2009, part of the draw was the fact that the Cambridge, MA-based start-up was positioning itself as a trailblazer in a raw field of oncology —cancer metabolism. The idea,...
Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers
Business Wire - Sun Apr 06, 9:30AM CDT
--- Data Presented at AACR Corroborate Company's Precision Medicine Approach in Targeting Cancer Metabolism; Company to Host Investor Webcast on April 6 -
